{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T09:06:27Z","timestamp":1776762387676,"version":"3.51.2"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"},{"name":"Janssen Scientific Affairs, LLC"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.thromres.2014.11.036","type":"journal-article","created":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T07:05:52Z","timestamp":1418454352000},"page":"217-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders"],"prefix":"10.1016","volume":"135","author":[{"given":"A.T.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Imfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Markham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Granziera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.11.036_bb0005","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/j.1538-7836.2007.02651.x","article-title":"Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists","volume":"5","author":"Goldhaber","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.036_bb0010","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/eurheartj\/ehi733","article-title":"Economic burden of cardiovascular diseases in the enlarged European Union","volume":"27","author":"Leal","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0015","first-page":"229","article-title":"Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation","volume":"10","author":"Buttar","year":"2005","journal-title":"Exp Clin Cardiol"},{"key":"10.1016\/j.thromres.2014.11.036_bb0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1160\/TH09-08-0582","article-title":"Anticoagulant therapy in critical organ ischaemia\/reperfusion injury","volume":"104","author":"Loubele","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.036_bb0025","first-page":"227","article-title":"The World Heart Federation's white book: impending global pandemic of cardiovascular diseases: challenges and opportunities for the prevention and control of cardiovascular diseases in developing countries and economies in transition","volume":"16","author":"Chockalingam","year":"2000","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.thromres.2014.11.036_bb0030","doi-asserted-by":"crossref","first-page":"245037","DOI":"10.1155\/2012\/245037","article-title":"Clinical use of aspirin in treatment and prevention of cardiovascular disease","volume":"2012","author":"Dai","year":"2012","journal-title":"Thrombosis"},{"key":"10.1016\/j.thromres.2014.11.036_bb0035","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1136\/hrt.2005.072173","article-title":"Cost of cardiovascular diseases in the United Kingdom","volume":"92","author":"Luengo-Fernandez","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2014.11.036_bb0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cpcardiol.2009.10.002","article-title":"Growing epidemic of coronary heart disease in low- and middle-income countries","volume":"35","author":"Gaziano","year":"2010","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.thromres.2014.11.036_bb0045","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0050","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0055","doi-asserted-by":"crossref","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0060","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0065","author":"Scottish Intercollegiate Guidelines Network"},{"key":"10.1016\/j.thromres.2014.11.036_bb0070","author":"American Academy of Orthopaedic Surgeons"},{"key":"10.1016\/j.thromres.2014.11.036_bb0075","author":"National Institute for Health and Clinical Excellence"},{"key":"10.1016\/j.thromres.2014.11.036_bb0080","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0085","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0090","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin: a historical and contemporary therapeutic overview","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2014.11.036_bb0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"Br Med J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0100","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-1-1","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations","volume":"1","author":"de Abajo","year":"2001","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.thromres.2014.11.036_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0140-6736(00)02493-4","article-title":"Pulmonary Embolism Prevention","volume":"356","author":"Cohen","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0120","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0125","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0130","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0135","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0140","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0150","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0155","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0160","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0165","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0175","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0180","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0185","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0190","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0195","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.036_bb0200","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0205","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial","volume":"105","author":"Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.036_bb0210","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0215","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2014.11.036_bb0220","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1302\/0301-620X.91B5.21691","article-title":"Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement","volume":"91","author":"Eriksson","year":"2009","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.thromres.2014.11.036_bb0225","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0230","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1472-8206.2011.00980.x","article-title":"Rivaroxaban for the prevention and treatment of venous thromboembolism","volume":"26","author":"Turpie","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.thromres.2014.11.036_bb0235","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.blre.2007.11.001","article-title":"Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism","volume":"22","author":"Watson","year":"2008","journal-title":"Blood Rev"},{"key":"10.1016\/j.thromres.2014.11.036_bb0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy\u2013III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients","volume":"308","year":"1994","journal-title":"Br Med J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0245","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/bmj.309.6963.1213","article-title":"Antiplatelet treatment for thromboprophylaxis: a step forward or backwards?","volume":"309","author":"Cohen","year":"1994","journal-title":"Br Med J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(05)74499-8","article-title":"Pulmonary Embolism Prevention","volume":"356","author":"Thomas","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0255","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-158-11-201306040-00004","article-title":"Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial","volume":"158","author":"Anderson","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0260","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-159-7-201310010-00017","article-title":"Aspirin versus low-molecular-weight heparin after total hip arthroplasty","volume":"159","author":"Granziera","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0265","author":"Food and Drug Administration"},{"key":"10.1016\/j.thromres.2014.11.036_bb0270","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0280","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group","volume":"349","author":"Anon.","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0285","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group","volume":"349","author":"Anon.","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0290","first-page":"3049","article-title":"Controlled cooperative trial of secondary prevention of cerebral ischemic accidents caused by atherosclerosis, using aspirin and dipyridamole","volume":"12","author":"Bousser","year":"1983","journal-title":"Presse Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0295","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0300","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0305","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0310","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","article-title":"Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"42","author":"Furie","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2014.11.036_bb0320","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.11.036_bb0325","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0330","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1067\/mva.2002.121847","article-title":"Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study","volume":"35","author":"Johnson","year":"2002","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.thromres.2014.11.036_bb0335","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0741-5214(98)70130-2","article-title":"Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure","volume":"28","author":"Sarac","year":"1998","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.thromres.2014.11.036_bb0340","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-147-8-200710160-00004","article-title":"Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial","volume":"147","author":"Glynn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0345","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3949\/ccjm.77a.09035","article-title":"Managing acute upper GI bleeding, preventing recurrences","volume":"77","author":"Albeldawi","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0350","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2014.11.036_bb0355","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fphar.2010.00126","article-title":"Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes","volume":"1","author":"Cea Soriano","year":"2010","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.thromres.2014.11.036_bb0360","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(80)90282-2","article-title":"Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man","volume":"2","author":"Hoftiezer","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0365","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00004836-199002000-00004","article-title":"Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy","volume":"12","author":"Jaszewski","year":"1990","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.thromres.2014.11.036_bb0370","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2036.1999.00470.x","article-title":"Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?","volume":"13","author":"Cole","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.11.036_bb0375","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2036.1999.00588.x","article-title":"Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions","volume":"13","author":"Dammann","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.11.036_bb0380","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1046\/j.1365-2036.2002.01332.x","article-title":"Effects of enteric-coated, low-dose aspirin on parameters of platelet function","volume":"16","author":"Van Hecken","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.thromres.2014.11.036_bb0385","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurheartj\/ehq030","article-title":"Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications","volume":"31","author":"Gersh","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0390","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1160\/TH13-04-0326","article-title":"Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation","volume":"110","author":"Cea Soriano","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.036_bb0395","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.thromres.2006.08.014","article-title":"Aspirin resistance","volume":"120","author":"Tran","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.036_bb0400","article-title":"Impact of aspirin resistance on outcomes among patients following coronary artery bypass grafting: exploratory analysis from randomized controlled trial (NCT01159639)","author":"Petricevic","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.thromres.2014.11.036_bb0405","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1136\/heartjnl-2012-302449","article-title":"Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study","volume":"98","author":"Mannacio","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.thromres.2014.11.036_bb0410","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \"resistance\" and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2014.11.036_bb0415","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0420","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.036_bb0425","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2013-305827","article-title":"The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial","author":"Ishikawa","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.thromres.2014.11.036_bb0430","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ahj.2011.04.006","article-title":"Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials","volume":"162","author":"Berger","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0435","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.2012.5034","article-title":"Association of aspirin use with major bleeding in patients with and without diabetes","volume":"307","author":"De Berardis","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2014.11.036_bb0440","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","article-title":"ISIS-2: 10year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"316","author":"Baigent","year":"1998","journal-title":"Br Med J"},{"key":"10.1016\/j.thromres.2014.11.036_bb0445","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials","volume":"119","author":"McQuaid","year":"2006","journal-title":"Am J Med"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:54:40Z","timestamp":1538009680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814006720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0049384814006720"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.036","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}